JP2011520868A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011520868A5 JP2011520868A5 JP2011509043A JP2011509043A JP2011520868A5 JP 2011520868 A5 JP2011520868 A5 JP 2011520868A5 JP 2011509043 A JP2011509043 A JP 2011509043A JP 2011509043 A JP2011509043 A JP 2011509043A JP 2011520868 A5 JP2011520868 A5 JP 2011520868A5
- Authority
- JP
- Japan
- Prior art keywords
- ppi
- composition
- low molecular
- stomach
- succinic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 100
- 239000000203 mixture Substances 0.000 claims description 56
- 239000002245 particle Substances 0.000 claims description 50
- 239000001384 succinic acid Substances 0.000 claims description 50
- 150000001735 carboxylic acids Chemical class 0.000 claims description 42
- 210000002784 stomach Anatomy 0.000 claims description 35
- 150000003839 salts Chemical class 0.000 claims description 33
- 230000027119 gastric acid secretion Effects 0.000 claims description 30
- 239000002775 capsule Substances 0.000 claims description 29
- 239000008194 pharmaceutical composition Substances 0.000 claims description 27
- 210000004027 cell Anatomy 0.000 claims description 12
- 239000004480 active ingredient Substances 0.000 claims description 9
- 229940126409 proton pump inhibitor Drugs 0.000 claims description 9
- 239000000612 proton pump inhibitor Substances 0.000 claims description 9
- 230000003111 delayed effect Effects 0.000 claims description 8
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims description 8
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical group O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims description 6
- 201000000052 gastrinoma Diseases 0.000 claims description 6
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 claims description 4
- 201000008629 Zollinger-Ellison syndrome Diseases 0.000 claims description 4
- 238000010521 absorption reaction Methods 0.000 claims description 4
- 208000000718 duodenal ulcer Diseases 0.000 claims description 4
- 230000002496 gastric effect Effects 0.000 claims description 4
- 230000005176 gastrointestinal motility Effects 0.000 claims description 4
- 230000002427 irreversible effect Effects 0.000 claims description 4
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 4
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 4
- 229960000381 omeprazole Drugs 0.000 claims description 4
- 208000024891 symptom Diseases 0.000 claims description 4
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 claims description 2
- YPELFRMCRYSPKZ-UHFFFAOYSA-N 4-amino-5-chloro-2-ethoxy-N-({4-[(4-fluorophenyl)methyl]morpholin-2-yl}methyl)benzamide Chemical compound CCOC1=CC(N)=C(Cl)C=C1C(=O)NCC1OCCN(CC=2C=CC(F)=CC=2)C1 YPELFRMCRYSPKZ-UHFFFAOYSA-N 0.000 claims description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 2
- KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 claims description 2
- 208000007882 Gastritis Diseases 0.000 claims description 2
- 206010019375 Helicobacter infections Diseases 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 claims description 2
- 108010016076 Octreotide Proteins 0.000 claims description 2
- 108091005804 Peptidases Proteins 0.000 claims description 2
- 239000004365 Protease Substances 0.000 claims description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 2
- 208000007107 Stomach Ulcer Diseases 0.000 claims description 2
- 206010042220 Stress ulcer Diseases 0.000 claims description 2
- 201000008736 Systemic mastocytosis Diseases 0.000 claims description 2
- 206010046274 Upper gastrointestinal haemorrhage Diseases 0.000 claims description 2
- 201000011032 Werner Syndrome Diseases 0.000 claims description 2
- 230000004913 activation Effects 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 229940072056 alginate Drugs 0.000 claims description 2
- 235000010443 alginic acid Nutrition 0.000 claims description 2
- 229920000615 alginic acid Polymers 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 229940088710 antibiotic agent Drugs 0.000 claims description 2
- 229960000794 baclofen Drugs 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- DCSUBABJRXZOMT-IRLDBZIGSA-N cisapride Chemical compound C([C@@H]([C@@H](CC1)NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)OC)N1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-IRLDBZIGSA-N 0.000 claims description 2
- 229960005132 cisapride Drugs 0.000 claims description 2
- DCSUBABJRXZOMT-UHFFFAOYSA-N cisapride Natural products C1CC(NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)C(OC)CN1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-UHFFFAOYSA-N 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims description 2
- 229960001253 domperidone Drugs 0.000 claims description 2
- FGXWKSZFVQUSTL-UHFFFAOYSA-N domperidone Chemical compound C12=CC=CC=C2NC(=O)N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2NC1=O FGXWKSZFVQUSTL-UHFFFAOYSA-N 0.000 claims description 2
- 230000002183 duodenal effect Effects 0.000 claims description 2
- 201000006549 dyspepsia Diseases 0.000 claims description 2
- 229960003276 erythromycin Drugs 0.000 claims description 2
- 201000005917 gastric ulcer Diseases 0.000 claims description 2
- 208000015419 gastrin-producing neuroendocrine tumor Diseases 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 210000000936 intestine Anatomy 0.000 claims description 2
- 229960004503 metoclopramide Drugs 0.000 claims description 2
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 claims description 2
- 229960004085 mosapride Drugs 0.000 claims description 2
- 230000000422 nocturnal effect Effects 0.000 claims description 2
- 229960002700 octreotide Drugs 0.000 claims description 2
- 210000001711 oxyntic cell Anatomy 0.000 claims description 2
- 208000000689 peptic esophagitis Diseases 0.000 claims description 2
- 210000000813 small intestine Anatomy 0.000 claims description 2
- -1 small molecule carboxylic acids Chemical class 0.000 claims description 2
- IKBKZGMPCYNSLU-RGVLZGJSSA-N tegaserod Chemical compound C1=C(OC)C=C2C(/C=N/NC(=N)NCCCCC)=CNC2=C1 IKBKZGMPCYNSLU-RGVLZGJSSA-N 0.000 claims description 2
- 229960002876 tegaserod Drugs 0.000 claims description 2
- 238000000034 method Methods 0.000 description 9
- 238000009472 formulation Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/120,599 | 2008-05-14 | ||
| US12/120,599 US7981908B2 (en) | 2005-05-11 | 2008-05-14 | Compositions and methods for inhibiting gastric acid secretion |
| PCT/IB2009/006176 WO2009138884A2 (en) | 2008-05-14 | 2009-05-14 | Compositions and methods for inhibiting gastric acid secretion |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014194754A Division JP2014240435A (ja) | 2008-05-14 | 2014-09-25 | 胃酸分泌を阻害するための組成物および方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011520868A JP2011520868A (ja) | 2011-07-21 |
| JP2011520868A5 true JP2011520868A5 (https=) | 2013-04-25 |
Family
ID=41319115
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011509043A Withdrawn JP2011520868A (ja) | 2008-05-14 | 2009-05-14 | 胃酸分泌を阻害するための組成物および方法 |
| JP2014194754A Pending JP2014240435A (ja) | 2008-05-14 | 2014-09-25 | 胃酸分泌を阻害するための組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014194754A Pending JP2014240435A (ja) | 2008-05-14 | 2014-09-25 | 胃酸分泌を阻害するための組成物および方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US7981908B2 (https=) |
| EP (1) | EP2296470A4 (https=) |
| JP (2) | JP2011520868A (https=) |
| AU (1) | AU2009247712C1 (https=) |
| CA (1) | CA2725437C (https=) |
| IL (1) | IL209296A0 (https=) |
| WO (1) | WO2009138884A2 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080020041A1 (en) * | 2004-10-19 | 2008-01-24 | Ayres James W | Enteric Coated Compositions that Release Active Ingredient(s) in Gastric Fluid and Intestinal Fluid |
| US7981908B2 (en) * | 2005-05-11 | 2011-07-19 | Vecta, Ltd. | Compositions and methods for inhibiting gastric acid secretion |
| US7803817B2 (en) | 2005-05-11 | 2010-09-28 | Vecta, Ltd. | Composition and methods for inhibiting gastric acid secretion |
| PL2046334T3 (pl) * | 2006-07-25 | 2015-02-27 | Vecta Ltd | Kompozycje i sposoby hamowania wydzielania kwasów żołądkowych z wykorzystaniem pochodnych małych kwasów dikarboksylowych w połączeniu z PPI |
| ES2744406T3 (es) * | 2013-02-13 | 2020-02-25 | Redhill Biopharma Ltd | Composiciones farmacéuticas para el tratamiento de helicobacter pylori |
| CN114315750B (zh) * | 2020-09-29 | 2024-05-10 | 鲁南制药集团股份有限公司 | 一种莫沙必利-丁二酸共晶 |
Family Cites Families (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2046334A (en) | 1933-02-25 | 1936-07-07 | Stay On Mfg Company | Utensil |
| US2343011A (en) | 1941-07-11 | 1944-02-29 | Huppert Oskar | Thio-protein plastic |
| SE7804231L (sv) | 1978-04-14 | 1979-10-15 | Haessle Ab | Magsyrasekretionsmedel |
| JPS59104326A (ja) * | 1982-12-04 | 1984-06-16 | Toyo Jozo Co Ltd | マクロライド抗生物質の安定な経口用製剤および安定化法 |
| SE8301182D0 (sv) | 1983-03-04 | 1983-03-04 | Haessle Ab | Novel compounds |
| JPS60193917A (ja) * | 1984-03-14 | 1985-10-02 | R P Shiila- Kk | 多重構造軟カプセル剤 |
| IL75400A (en) | 1984-06-16 | 1988-10-31 | Byk Gulden Lomberg Chem Fab | Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same |
| JPS6150978A (ja) | 1984-08-16 | 1986-03-13 | Takeda Chem Ind Ltd | ピリジン誘導体およびその製造法 |
| AU4640985A (en) | 1984-08-31 | 1986-03-06 | Nippon Chemiphar Co. Ltd. | Benzimidazole derivatives |
| JPS6194717A (ja) * | 1984-10-17 | 1986-05-13 | Takara Co Ltd | 合成樹脂製人形等の成形方法およびその装置 |
| US4767627A (en) | 1985-05-29 | 1988-08-30 | Merck & Co., Inc. | Drug delivery device which can be retained in the stomach for a controlled period of time |
| US5238686A (en) * | 1986-03-27 | 1993-08-24 | Kinaform Technology, Inc. | Sustained-release pharmaceutical preparation |
| GB2189699A (en) | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated acid-labile medicaments |
| GB2189698A (en) | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated omeprazole tablets |
| GB8621425D0 (en) | 1986-09-05 | 1986-10-15 | Smith Kline French Lab | Compounds |
| IL88507A (en) | 1987-12-03 | 1993-02-21 | Smithkline Beckman Intercredit | 2,4-diaminoquinazolines, process for their preparation and pharmaceutical compositions comprising them |
| SE8804629D0 (sv) | 1988-12-22 | 1988-12-22 | Ab Haessle | New therapeutically active compounds |
| JP2656338B2 (ja) | 1989-01-31 | 1997-09-24 | 日東電工株式会社 | 口腔粘膜貼付製剤 |
| CA2015981A1 (en) | 1989-05-10 | 1990-11-10 | Thomas H. Brown | Compounds |
| US5048353A (en) | 1990-03-01 | 1991-09-17 | Beloit Corporation | Method and apparatus for roll profile measurement |
| JPH03287103A (ja) | 1990-04-02 | 1991-12-17 | Seiko Epson Corp | カラーフィルターの形成法 |
| SE9002206D0 (sv) | 1990-06-20 | 1990-06-20 | Haessle Ab | New compounds |
| DE69131627T2 (de) | 1990-06-20 | 2000-04-27 | Astra Ab Soedertaelje | Dialkoxypyridinylbenzimidazolderivate, verfahren zur herstellung und ihre pharmazeutische verwendung |
| JPH06510547A (ja) | 1992-07-06 | 1994-11-24 | コミスサローバ，イリナ アレクセエフナ | 抗アルコール活性を有し、エネルギー代謝と胃粘膜の酸を生成し分泌する機能とを刺激し、放射能防御活性と抗コレラ活性を有する医薬組成物 |
| US7795239B2 (en) | 1992-07-27 | 2010-09-14 | Mueller Medical International LLC | Saccharide compositions and method of use |
| SE9301489D0 (sv) | 1993-04-30 | 1993-04-30 | Ab Astra | Veterinary composition |
| SE9301830D0 (sv) | 1993-05-28 | 1993-05-28 | Ab Astra | New compounds |
| SE9302396D0 (sv) | 1993-07-09 | 1993-07-09 | Ab Astra | A novel compound form |
| JP2896532B2 (ja) | 1994-08-13 | 1999-05-31 | ユーハン コーポレーション | 新規なピリミジン誘導体およびその製造方法 |
| ES2094694B1 (es) * | 1995-02-01 | 1997-12-16 | Esteve Quimica Sa | Nueva formulacion farmaceuticamente estable de un compuesto de bencimidazol y su proceso de obtencion. |
| SE9500422D0 (sv) * | 1995-02-06 | 1995-02-06 | Astra Ab | New oral pharmaceutical dosage forms |
| US6132768A (en) * | 1995-07-05 | 2000-10-17 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Oral pharmaceutical composition with delayed release of active ingredient for reversible proton pump inhibitors |
| US6489346B1 (en) | 1996-01-04 | 2002-12-03 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
| US6645988B2 (en) | 1996-01-04 | 2003-11-11 | Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
| US6699885B2 (en) | 1996-01-04 | 2004-03-02 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and methods of using same |
| US5840737A (en) | 1996-01-04 | 1998-11-24 | The Curators Of The University Of Missouri | Omeprazole solution and method for using same |
| SE512835C2 (sv) | 1996-01-08 | 2000-05-22 | Astrazeneca Ab | Doseringsform innehållande en mångfald enheter alla inneslutande syralabil H+K+ATPas-hämmare |
| US5677302A (en) | 1996-02-26 | 1997-10-14 | Apotex Inc. | Thiadiazole compounds useful as proton pump inhibitors |
| US5972389A (en) | 1996-09-19 | 1999-10-26 | Depomed, Inc. | Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter |
| US5800832A (en) | 1996-10-18 | 1998-09-01 | Virotex Corporation | Bioerodable film for delivery of pharmaceutical compounds to mucosal surfaces |
| SE9702533D0 (sv) * | 1997-07-01 | 1997-07-01 | Astra Ab | New oral formulation |
| US6296876B1 (en) | 1997-10-06 | 2001-10-02 | Isa Odidi | Pharmaceutical formulations for acid labile substances |
| ATE500815T1 (de) | 1997-12-08 | 2011-03-15 | Dietrich Rango | Neue suppositoriumsform mit säureempfindlichem wirkstoff |
| IT1296980B1 (it) * | 1997-12-17 | 1999-08-03 | Istituto Pirri S R L | Capsula doppia come forma farmaceutica per la somministrazione di principi attivi in terapie multiple |
| SE9704870D0 (sv) | 1997-12-22 | 1997-12-22 | Astra Ab | New pharmaceutical formulation I |
| CA2331834A1 (en) | 1998-06-18 | 1999-12-23 | Michal Y. Chowers | Pharmaceutical compositions for the treatment of helicobacter pylori-associated disorders |
| SE9902386D0 (sv) | 1999-06-22 | 1999-06-22 | Astra Ab | New formulation |
| US6228400B1 (en) | 1999-09-28 | 2001-05-08 | Carlsbad Technology, Inc. | Orally administered pharmaceutical formulations of benzimidazole derivatives and the method of preparing the same |
| US7365047B1 (en) | 1999-09-28 | 2008-04-29 | The Regents Of The University Of California | Use of pentagastrin to inhibit gastric acid secretion or as a diuretic |
| US7429599B2 (en) | 2000-12-06 | 2008-09-30 | Signal Pharmaceuticals, Llc | Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK |
| US20030049204A1 (en) | 2001-04-24 | 2003-03-13 | Mcgill University | Individualization of therapy with gastroesophageal reflux disease agents |
| US20030235628A1 (en) * | 2001-09-19 | 2003-12-25 | Rajneesh Taneja | Methods and pharmaceutical formulations for protecting pharmaceutical compounds from acidic environments |
| US20030175360A1 (en) * | 2002-02-22 | 2003-09-18 | Renzo Luzzatti | Symptomatic relief of gastrointestinal disorders |
| US20030181488A1 (en) | 2002-03-07 | 2003-09-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof |
| JP2005528383A (ja) * | 2002-04-10 | 2005-09-22 | ミラー，フレッド，エイチ． | 多重相・複数コンパートメントカプセルシステム |
| WO2003103592A2 (en) | 2002-06-06 | 2003-12-18 | University Of Washington | Covalent conjugates between artemisinin-related endoperoxides and iron-carrying proteins and methods of use |
| ES2578252T3 (es) * | 2002-09-24 | 2016-07-22 | Gumlink A/S | Goma de mascar que comprende al menos dos polímeros biodegradables diferentes |
| IL152289A0 (en) | 2002-10-14 | 2003-05-29 | Vectabiotics Ltd | Method and composition for inhibiting h.pylori infection in a mammalian tissue |
| WO2005020879A2 (en) | 2003-08-27 | 2005-03-10 | Vecta Ltd. | Compositions for treating pathologies that necessitate suppression of gastric acid secretion |
| US20060135406A1 (en) | 2002-10-14 | 2006-06-22 | Sabina Glozman | Compositions and methods for treating pathologies that necessitate suppression of gastric acid secretion |
| US20060127489A1 (en) * | 2002-10-24 | 2006-06-15 | Michael Crothers | Targeted delivery |
| US6866653B2 (en) * | 2002-10-31 | 2005-03-15 | Kyongtae T. Bae | Method and apparatus for sequential delivery of multiple injectable substances stored in a prefilled syringe |
| GB2394895A (en) | 2002-11-06 | 2004-05-12 | Cipla Ltd | Proton pump inhibitor composition in paste form |
| US20040248942A1 (en) | 2003-02-20 | 2004-12-09 | Bonnie Hepburn | Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid |
| WO2004112756A1 (en) | 2003-06-26 | 2004-12-29 | Isa Odidi | Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient |
| WO2005020954A2 (en) | 2003-09-03 | 2005-03-10 | Agi Therapeutics Limited | Proton pump inhibitor formulations, and methods of preparing and using such formulations |
| US7211568B2 (en) | 2003-12-18 | 2007-05-01 | Kosan Biosciences Incorporated | 9-Desoxoerythromycin compounds as prokinetic agents |
| RS20050796A (sr) | 2004-01-06 | 2007-08-03 | Panacea Biotec Ltd., | Farmaceutske smeše koje sadrže inhibitor protonske pumpe i prokinetičko sredstvo |
| US20050181052A1 (en) | 2004-02-17 | 2005-08-18 | Patel Satishkumar A. | Lansoprazole microtablets |
| CA2561700A1 (en) | 2004-04-16 | 2005-12-15 | Santarus, Inc. | Combination of proton pump inhibitor, buffering agent, and prokinetic agent |
| BRPI0516308A2 (pt) | 2004-10-04 | 2010-06-15 | Qlt Usa Inc | composição fluida, métodos de tratamento de uma doença ou disfunção, métodos de liberação local ou sistêmica de um agente biológico, implantes, método de formação de um implante, kit de agente biológico e usos de uma composição fluida |
| LT2801354T (lt) | 2004-10-08 | 2017-06-26 | Forward Pharma A/S | Kontroliuojamo atpalaidavimo farmacinės kompozicijos, apimančios fumaro rūgšties esterį |
| CA2598696A1 (en) * | 2005-02-23 | 2006-08-31 | Surmodics, Inc. | Implantable medical articles having laminin coatings and methods of use |
| US7981908B2 (en) * | 2005-05-11 | 2011-07-19 | Vecta, Ltd. | Compositions and methods for inhibiting gastric acid secretion |
| US7803817B2 (en) | 2005-05-11 | 2010-09-28 | Vecta, Ltd. | Composition and methods for inhibiting gastric acid secretion |
| PL226695B1 (pl) | 2006-07-03 | 2017-08-31 | Danuta Kruszewska | Środek do zastosowania w zapobieganiu i/lub hamowaniu kolonizacji Helicobacter pylori, zastosowanie soli kwasu alfa‑ketoglutarowego z metalami alkalicznymi i ziem alkalicznych do wytwarzania środka leczniczego oraz dodatku do żywności do zapobiegania i/lub hamowania kolonizacji Helicobacter pylori |
| PL2046334T3 (pl) | 2006-07-25 | 2015-02-27 | Vecta Ltd | Kompozycje i sposoby hamowania wydzielania kwasów żołądkowych z wykorzystaniem pochodnych małych kwasów dikarboksylowych w połączeniu z PPI |
-
2008
- 2008-05-14 US US12/120,599 patent/US7981908B2/en not_active Expired - Fee Related
-
2009
- 2009-05-14 US US12/991,746 patent/US9132082B2/en not_active Expired - Fee Related
- 2009-05-14 AU AU2009247712A patent/AU2009247712C1/en not_active Ceased
- 2009-05-14 CA CA2725437A patent/CA2725437C/en not_active Expired - Fee Related
- 2009-05-14 JP JP2011509043A patent/JP2011520868A/ja not_active Withdrawn
- 2009-05-14 EP EP20090746179 patent/EP2296470A4/en not_active Withdrawn
- 2009-05-14 WO PCT/IB2009/006176 patent/WO2009138884A2/en not_active Ceased
-
2010
- 2010-11-14 IL IL209296A patent/IL209296A0/en unknown
-
2011
- 2011-04-19 US US13/089,535 patent/US9370481B2/en not_active Expired - Fee Related
-
2014
- 2014-09-25 JP JP2014194754A patent/JP2014240435A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Maradey-Romero et al. | New and future drug development for gastroesophageal reflux disease | |
| JP2011520868A5 (https=) | ||
| US9278080B2 (en) | Compositions and methods for inhibiting gastric acid secretion | |
| RU2013106514A (ru) | Способы лечения нарушений желудочно-кишечного тракта независимо от потребления пищи | |
| CA2605839A1 (en) | Stabilized composition of a proton pump inhibitor | |
| RS52233B (sr) | Farmaceutski dozirni oblik koji obuhvata granule kao i njegov postupak proizvodnje | |
| JP2014240435A (ja) | 胃酸分泌を阻害するための組成物および方法 | |
| JP5474541B2 (ja) | 小さいジカルボン酸の誘導体と組み合わせてｐｐｉを用いる胃酸分泌を阻害する組成物および方法 | |
| ES2829285T3 (es) | Administración de AINE y composiciones, métodos y sistemas relacionados | |
| RU2005122465A (ru) | (-)-энантиомер тенатопразола и его применение в терапии | |
| US20040082514A1 (en) | Methods for treatment of helicobacter pylori-associated disorders | |
| WO2013122554A1 (en) | Pellet formulations comprising esomeprazole | |
| TW201513895A (zh) | 調配物 | |
| ME00452B (me) | Mikrokapsule za odloženo i kontrolisano oslobadjanje perindoprila | |
| TR201502081A2 (tr) | Antiülseratif farmasötik terkipler. | |
| KR960015143B1 (ko) | 벤즈이미다졸유도체를 함유하는 신규 경구형 제제 및 그 제조방법 | |
| Sonagre et al. | Current Advances in Technology of Proton Pump Inhibitor Formulations | |
| TR201605487A1 (tr) | Anti̇ülserati̇f farmasöti̇k terki̇pler | |
| TR201503285A2 (tr) | Anti̇ülserati̇f farmasöti̇k terki̇pler | |
| WO2013122553A1 (en) | A pharmaceutical formulation comprising an atp-ase inhibitor and method for this formulation | |
| TR201511176A2 (tr) | Anti̇ülserati̇f farmasöti̇k terki̇pler | |
| TR201606324A1 (tr) | Anti̇ülserati̇f farmasöti̇k terki̇pler | |
| TR201605072A1 (tr) | Anti̇ülserati̇f farmasöti̇k terki̇pler | |
| TR201501583A2 (tr) | Antiülseratif farmasötik terkipler. |